<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: communications", fill: "#da70d6"},
{source: "1: communications", target: "1: statements about", fill: "#da70d6"},
{source: "1: statements about", target: "1: discovery", fill: "#da70d6"},
{source: "1: discovery", target: "1: development", fill: "#da70d6"},
{source: "1: development", target: "1: intellectual property", fill: "#da70d6"},
{source: "1: communications", target: "17: dependent upon revenue generated from", fill: "#6d9bc3"},
{source: "17: dependent upon revenue generated from", target: "17: collaborative", fill: "#6d9bc3"},
{source: "17: collaborative", target: "17: arrangements", fill: "#6d9bc3"},
{source: "17: arrangements", target: "17: licensing efforts over", fill: "#6d9bc3"},
{source: "17: licensing efforts over", target: "17: next several years", fill: "#6d9bc3"},
{source: "17: dependent upon revenue generated from", target: "18: become profitable", fill: "#f7e98e"},
{source: "18: become profitable", target: "18: either alone", fill: "#f7e98e"},
{source: "18: either alone", target: "18: collaborators must", fill: "#f7e98e"},
{source: "18: collaborators must", target: "18: successfully", fill: "#f7e98e"},
{source: "18: successfully", target: "18: manufacture", fill: "#f7e98e"},
{source: "18: manufacture", target: "18: current product candidates", fill: "#f7e98e"},
{source: "18: current product candidates", target: "18: display technology", fill: "#f7e98e"},
{source: "18: display technology", target: "18: generate research funding", fill: "#f7e98e"},
{source: "18: generate research funding", target: "18: licensing revenue", fill: "#f7e98e"},
{source: "18: become profitable", target: "19: significant product sales revenue", fill: "#fffff0"},
{source: "19: significant product sales revenue", target: "19: significant royalties on", fill: "#fffff0"},
{source: "19: significant royalties on", target: "19: technology", fill: "#fffff0"},
{source: "19: significant product sales revenue", target: "24: future capital requirements will depend on", fill: "#00fa9a"},
{source: "24: future capital requirements will depend on", target: "24: drug discovery", fill: "#00fa9a"},
{source: "24: drug discovery", target: "24: development", fill: "#00fa9a"},
{source: "24: development", target: "24: commercialize", fill: "#00fa9a"},
{source: "24: commercialize", target: "24: candidates", fill: "#00fa9a"},
{source: "24: candidates", target: "24: existing collaborative", fill: "#00fa9a"},
{source: "24: existing collaborative", target: "24: arrangements", fill: "#00fa9a"},
{source: "24: arrangements", target: "24: entering into additional ones", fill: "#00fa9a"},
{source: "24: entering into additional ones", target: "24: commercialization", fill: "#00fa9a"},
{source: "24: commercialization", target: "24: collaborators", fill: "#00fa9a"},
{source: "24: collaborators", target: "24: manufacture", fill: "#00fa9a"},
{source: "24: manufacture", target: "24: materials used", fill: "#00fa9a"},
{source: "24: materials used", target: "24: competing technological", fill: "#00fa9a"},
{source: "24: competing technological", target: "24: market developments", fill: "#00fa9a"},
{source: "24: market developments", target: "24: intellectual property", fill: "#00fa9a"},
{source: "24: intellectual property", target: "24: additional capital equipment purchases", fill: "#00fa9a"},
{source: "24: future capital requirements will depend on", target: "29: seek funds through arrangements with collaborators", fill: "#ecebbd"},
{source: "29: seek funds through arrangements with collaborators", target: "29: relinquish rights", fill: "#ecebbd"},
{source: "29: relinquish rights", target: "29: technologies", fill: "#ecebbd"},
{source: "29: technologies", target: "29: product candidates", fill: "#ecebbd"},
{source: "29: product candidates", target: "29: would otherwise pursue on", fill: "#ecebbd"},
{source: "29: seek funds through arrangements with collaborators", target: "30: biopharmaceutical", fill: "#f56991"},
{source: "30: biopharmaceutical", target: "30: clinical trials", fill: "#f56991"},
{source: "30: clinical trials", target: "30: regulatory approvals which could substantially delay", fill: "#f56991"},
{source: "30: regulatory approvals which could substantially delay", target: "30: development", fill: "#f56991"},
{source: "30: biopharmaceutical", target: "START_HERE", fill: "#f56991"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_software">Collaborative software</a></td>
      <td>Collaborative software or groupware is application software designed to help people working on a common task to attain their goals. One of the earliest definitions of groupware is "intentional group processes plus software to support them".As regards available interaction, collaborative software may be divided into: real-time collaborative editing platforms that allow multiple users to engage in live, simultaneous and reversible editing of a single file (usually a document),  and version control (also known as revision control and source control) platforms, which allow separate users to make parallel edits to a file, while preserving every saved edit by every user as multiple files (that are variants of the original file).Collaborative software is a broad concept that overlaps considerably with computer-supported cooperative work (CSCW).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kendrick_Lamar">Kendrick Lamar</a></td>
      <td>Kendrick Lamar Duckworth (born June 17, 1987) is an American rapper, songwriter, and record producer. He is often cited as one of the most influential rappers of his generation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_the_Internet">Commercialization of the Internet</a></td>
      <td>The commercialization of the Internet refers to the creation and management of online services principally for financial gain. It typically involves the increasing monetization of network services and consumer products mediated through the varied use of Internet technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Agilent_Technologies">Agilent Technologies</a></td>
      <td>Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biopharmaceutical">Biopharmaceutical</a></td>
      <td>A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lundbeck_Seattle_Biopharmaceuticals">Lundbeck Seattle Biopharmaceuticals</a></td>
      <td>Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Formerly known as Alder Biopharmaceuticals, it specializes in therapeutic monoclonal antibodies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mapp_Biopharmaceutical">Mapp Biopharmaceutical</a></td>
      <td>Mapp Biopharmaceutical is an American pharmaceutical company founded in 2003 by Larry Zeitlin and Kevin Whaley. Mapp Biopharmaceutical is based in San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sino_Biopharmaceutical_Limited">Sino Biopharmaceutical Limited</a></td>
      <td>Sino Biopharmaceutical Limited (SEHK: 1177|Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司; pinyin: zhōng guó shēng wù zhì yào yǒu xiàn gōng sī), shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.\nBeing a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Intas_Pharmaceuticals">Intas Pharmaceuticals</a></td>
      <td>Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad, Gujarat.\n\n\n== History ==\nThe company was founded by Hasmukh Chudgar in 1977 and was incorporated in 1985.In 2013, ChrysCapital acquired 16.14% stake in the company, and in 2015, ChrysCapital subsequently sold 10.13% to Singapore-based Temasek Holdings and in 2017, it further diluted 3.01% stake to Capital International.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/BioDrugs">BioDrugs</a></td>
      <td>BioDrugs is a peer-reviewed pharmacology journal. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biopharmaceutics_Classification_System">Biopharmaceutics Classification System</a></td>
      <td>The Biopharmaceutics Classification System is a system to differentiate the drugs on the basis of their solubility and permeability.This system restricts the prediction using the parameters solubility and intestinal permeability. The solubility classification is based on a United States Pharmacopoeia (USP) aperture.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>DYAX CORP      ITEM 1A        RISK FACTORS       This Annual Report on Form 10-K and certain other <font color="blue">communications</font> made by us     contain forward-looking statements, including <font color="blue">statements about</font> our growth     and  future  operating results, <font color="blue">discovery</font> and <font color="blue">development</font> of products,     strategic  alliances  and <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>We often use the words or phrases of expectation     or <font color="blue">uncertainty</font> like “believe,” “anticipate,” “plan,” “expect,” “intend,”     “project,” “future,” “may,” “will,” “could,” “would” and similar words to     help identify forward-looking statements</td>
    </tr>
    <tr>
      <td><font color="blue">Statements  </font>that  are  not  historical  facts are <font color="blue">based on</font> our current     <font color="blue">expectations</font> and beliefs including our <font color="blue"><font color="blue">assumption</font>s</font>, estimates, forecasts and     <font color="blue">projections</font>  for our business and the industry and markets in which we     compete</td>
    </tr>
    <tr>
      <td>These statements are not <font color="blue">guarantees</font> of <font color="blue">future performance</font> and     involve certain risks, <font color="blue">uncertainties</font> and <font color="blue"><font color="blue">assumption</font>s</font>, which are <font color="blue">difficult</font> to     predict</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">cannot assure</font> investors</font> that our <font color="blue">expectations</font> and <font color="blue">beliefs will</font>     prove to have been correct</td>
    </tr>
    <tr>
      <td><font color="blue">Important </font><font color="blue">factors could</font> cause our actual results     to <font color="blue">differ <font color="blue">materially</font> from</font> those indicated or implied by forward-looking     statements</td>
    </tr>
    <tr>
      <td>Factors that could cause or contribute to <font color="blue">such differences</font>     include the <font color="blue">factors discussed</font> below</td>
    </tr>
    <tr>
      <td>We caution you not to place undue     <font color="blue">reliance on</font> these forward looking statements, which speak only as of the     <font color="blue">date on which</font> they are made</td>
    </tr>
    <tr>
      <td>We undertake <font color="blue">no intention</font> or <font color="blue">obligation</font> to     update or revise any forward-looking statements, whether as a result of new     information, <font color="blue">future events</font> or otherwise</td>
    </tr>
    <tr>
      <td>15     ______________________________________________________________________       We  have a history of operating losses and expect to <font color="blue">incur <font color="blue">significant</font></font>     <font color="blue">additional</font> operating losses</td>
    </tr>
    <tr>
      <td>We  have  incurred operating <font color="blue">losses since</font> our inception in 1989</td>
    </tr>
    <tr>
      <td>As of     <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of approximately dlra182dtta3     million</td>
    </tr>
    <tr>
      <td>We expect to incur substantial <font color="blue">additional</font> operating <font color="blue">losses over</font> the     <font color="blue"><font color="blue">next several years</font> as</font> our research, <font color="blue">development</font>, pre-clinical testing and     <font color="blue">clinical trial</font> <font color="blue">activities</font> increase, <font color="blue">particularly</font> <font color="blue">with respect</font> to our current     lead  <font color="blue">product candidate</font>, DX-88</td>
    </tr>
    <tr>
      <td>We have not generated any <font color="blue">revenue from</font>     product  sales  to  date,  and  it is possible that we will never have     <font color="blue">significant</font>, if any, <font color="blue">product sales revenue</font></td>
    </tr>
    <tr>
      <td>Currently, we generate <font color="blue">revenue from</font> <font color="blue">collaborators</font> through research and     <font color="blue">development</font> funding and <font color="blue">through license</font> and <font color="blue">maintenance fees</font> that we receive     in <font color="blue">connection with</font> the licensing of our <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font></td>
    </tr>
    <tr>
      <td>We expect     to continue to be <font color="blue">dependent upon revenue generated from</font> our <font color="blue">collaborative</font>     <font color="blue">arrangements</font> and our <font color="blue">licensing efforts over</font> the <font color="blue">next several years</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">become profitable</font>, we, <font color="blue">either alone</font> or with our <font color="blue">collaborators</font>, must     <font color="blue">successfully</font> develop, <font color="blue">manufacture</font> and market our current <font color="blue">product candidate</font>s,     including DX-88, and other products and continue to leverage our phage     <font color="blue">display <font color="blue">technology</font></font> to <font color="blue">generate research funding</font> and <font color="blue">licensing revenue</font></td>
    </tr>
    <tr>
      <td>It is     possible  that we will never have <font color="blue">significant</font> <font color="blue">product sales revenue</font> or     receive <font color="blue">significant</font> royalties on our licensed <font color="blue">product candidate</font>s or licensed     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We may be unable to raise the capital that we will need to sustain our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect that existing cash, cash equivalents, and short-term <font color="blue">investment</font>s     plus  anticipated cash flow from product <font color="blue">development</font>, license fees and     <font color="blue"><font color="blue">collaborations</font> will</font> be sufficient to support our current operating plans     into 2007</td>
    </tr>
    <tr>
      <td>We may, however, need or choose to raise <font color="blue">additional</font> funds before     then</td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> funds if our <font color="blue">cash requirements exceed</font> our     current <font color="blue">expectations</font> or if we <font color="blue">generate less revenue than</font> we expect</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital requirements will depend on</font> many factors, including:       ·       the progress of our drug <font color="blue">discovery</font> and <font color="blue">development</font> programs;       ·       our ability to develop and <font color="blue">commercialize</font> our <font color="blue">product candidate</font>s;       ·       maintaining or expanding our existing <font color="blue">collaborative</font> and license     <font color="blue">arrangements</font> and entering into <font color="blue">additional</font> ones;       ·       the progress of the <font color="blue">development</font> and <font color="blue">commercialization</font> of milestone     and royalty-bearing compounds by our <font color="blue">collaborators</font> and licensees;       ·        our  decision  to  <font color="blue">manufacture</font>  <font color="blue">materials used</font> in our product     <font color="blue">candidates</font>;       ·       <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s;       ·       costs of defending our patents and other <font color="blue"><font color="blue">intellectual</font> property</font>     rights; and       ·       the amount and timing of <font color="blue">additional</font> capital equipment purchases</td>
    </tr>
    <tr>
      <td>We also may seek <font color="blue">additional</font> funding through <font color="blue">collaborative</font> <font color="blue">arrangements</font> and     public or <font color="blue">private financings</font></td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">financing on</font>     acceptable terms or at all or we may not be able to <font color="blue">enter into</font> <font color="blue">additional</font>     <font color="blue">collaborative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>In addition, the terms of any <font color="blue">financing may</font>     <font color="blue"><font color="blue">adversely</font> affect</font> the holdings or the rights of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we are     unable to obtain <font color="blue">funding on</font> a <font color="blue">timely basis</font>, we may be required to curtail     <font color="blue">significant</font>ly one or more of our research or <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We also     could be required to seek funds through <font color="blue">arrangements</font> with <font color="blue">collaborators</font> or     others that may require us to <font color="blue">relinquish rights</font> to some of our <font color="blue">technologies</font>,     <font color="blue">product candidate</font>s or products that we <font color="blue">would otherwise pursue on</font> our own</td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       Our <font color="blue">biopharmaceutical</font> or diagnostic <font color="blue">product candidate</font>s must undergo rigorous     <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">regulatory</font> approvals, which could substantially delay or     prevent their <font color="blue">development</font> or marketing</td>
    </tr>
    <tr>
      <td>Any <font color="blue">biopharmaceutical</font> or <font color="blue">diagnostic product</font> that we develop will be subject     to rigorous <font color="blue"><font color="blue">clinical trial</font>s</font> and an extensive <font color="blue">regulatory</font> approval process     <font color="blue">implemented by</font> the Food and Drug Administration (FDA) and <font color="blue">analogous</font> foreign     <font color="blue">regulatory</font>  agencies</td>
    </tr>
    <tr>
      <td>This  approval process is <font color="blue">typically lengthy</font> and     expensive, and approval is <font color="blue">never certain</font></td>
    </tr>
    <tr>
      <td>Positive results from pre-clinical     studies and early <font color="blue"><font color="blue">clinical trial</font>s</font> do not ensure positive results in late     stage  clinical  trials  designed to <font color="blue">permit application</font> for <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>We do not know when, or if, our current <font color="blue"><font color="blue">clinical trial</font>s</font> will be     completed</td>
    </tr>
    <tr>
      <td>We <font color="blue">also cannot <font color="blue">accurately</font> predict</font> when other planned clinical     <font color="blue">trials will begin</font> or be completed</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors affect patient enrollment</font>,     including the size of the <font color="blue">patient population</font>, the proximity of patients to     clinical  sites,  the  <font color="blue">eligibility criteria</font> for the trial, alternative     therapies,  competing  clinical  trials and <font color="blue">new drugs approved</font> for the     <font color="blue">conditions</font> we are <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>For example, four other companies are     conducting <font color="blue"><font color="blue">clinical trial</font>s</font> of <font color="blue">treatments</font> for HAE and have announced plans     for  trials  that  are seeking or likely to seek patients with <font color="blue">HAE In     </font>addition, competition for patients in <font color="blue">cardiovascular disease trials</font> is     <font color="blue"><font color="blue">particularly</font> intense</font> because of the limited number of <font color="blue">leading cardiologists</font>     and the <font color="blue">geographic concentration</font> of <font color="blue">major clinical centers</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">delays may increase</font> our costs and slow down our product     <font color="blue">development</font> and the <font color="blue">regulatory</font> approval process</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font>     <font color="blue">costs will also increase</font> if we need to perform more or <font color="blue">larger clinical</font>     <font color="blue">trials than</font> planned</td>
    </tr>
    <tr>
      <td>The occurrence of any of these <font color="blue">events will delay</font> our     ability to generate <font color="blue">revenue from</font> product sales and impair our ability to     <font color="blue">become profitable</font>, which may cause us to have insufficient <font color="blue">capital resources</font>     to support our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because of the risks and <font color="blue">uncertainties</font> in <font color="blue">biopharmaceutical</font> <font color="blue">development</font>,     products that we or our <font color="blue">collaborators</font> develop could take a <font color="blue">significant</font>ly     longer time to gain <font color="blue">regulatory</font> approval than we expect or <font color="blue">may never gain</font>     approval</td>
    </tr>
    <tr>
      <td>If  we  or our <font color="blue">collaborators</font> do not receive these <font color="blue">necessary</font>     approvals, we will not be able to generate substantial product or royalty     revenues  and  may not <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We and our <font color="blue">collaborators</font> may     encounter <font color="blue">significant</font> delays or excessive costs in our efforts to secure     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td>Factors that raise <font color="blue">uncertainty</font> in obtaining these     <font color="blue">regulatory</font> approvals include the following:       ·        we must <font color="blue">demonstrate</font> through <font color="blue"><font color="blue">clinical trial</font>s</font> that the proposed     product is safe and <font color="blue">effective</font> for its <font color="blue">intended use</font>;       ·        we  have limited experience in conducting the <font color="blue"><font color="blue">clinical trial</font>s</font>     <font color="blue">necessary</font> to obtain <font color="blue">regulatory</font> approval; and       ·        data  obtained  from pre-clinical and <font color="blue">clinical <font color="blue">activities</font></font> are     susceptible to varying interpretations, which could delay, limit or prevent     <font color="blue">regulatory</font> approvals</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>authorities may delay, suspend or terminate <font color="blue"><font color="blue">clinical trial</font>s</font> at     any time if they believe that the <font color="blue">patients participating</font> in trials are being     exposed to unacceptable <font color="blue">health risks</font> or if they <font color="blue">find <font color="blue">deficiencies</font></font> in the     <font color="blue"><font color="blue">clinical trial</font> procedures</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Investigational New Drug Applications </font>for our     <font color="blue">recombinant</font> protein DX-88, for example, were placed on clinical hold by the     <font color="blue">FDA in May </font>2004, following the FDA’s <font color="blue">evaluation</font> of <font color="blue">certain animal test data</font>     submitted  by  us</td>
    </tr>
    <tr>
      <td>Although the study was allowed to continue, we were     required by the FDA to conduct <font color="blue">additional</font> testing at <font color="blue">additional</font> expense, and     there is no guarantee that we would be able to resolve similar issues in the     future,  either  as  quickly,  or  at  all</td>
    </tr>
    <tr>
      <td>In  addition,  our or our     <font color="blue">collaborators</font>’ failure to comply with applicable <font color="blue">regulatory</font> requirements may     result in criminal <font color="blue">prosecution</font>, civil penalties and other actions that could     impair our ability to conduct our business</td>
    </tr>
    <tr>
      <td>We initiated a <font color="blue">Phase III </font><font color="blue">clinical trial</font> of DX-88 for the treatment of HAE in     <font color="blue">December </font>2005</td>
    </tr>
    <tr>
      <td>Before filing a Biologic License Application (BLA) for     marketing approval of this product in this <font color="blue">indication</font>, which we plan to     commence filing during the second half of 2006, we will need to complete     this <font color="blue">Phase III </font>trial</td>
    </tr>
    <tr>
      <td>HAE is an <font color="blue">indication</font> with a <font color="blue">particularly</font> small patient     population, and our planned <font color="blue">Phase III </font>trial may, for       17     ______________________________________________________________________       this  or  any  of  the other <font color="blue">reasons described</font> above, take <font color="blue">longer than</font>     anticipated to initiate and/or to complete</td>
    </tr>
    <tr>
      <td>We  lack experience in conducting <font color="blue"><font color="blue">clinical trial</font>s</font>, handling <font color="blue">regulatory</font>     processes, and <font color="blue">conducting sales</font> and <font color="blue">marketing <font color="blue">activities</font></font>, any or all of     which   may   <font color="blue">adversely</font>   affect  our  ability  to  <font color="blue">commercialize</font>  any     <font color="blue">biopharmaceutical</font>s that we may develop</td>
    </tr>
    <tr>
      <td>We have hired experienced clinical <font color="blue">development</font>, <font color="blue">regulatory</font>, and marketing     staff to develop and supervise our <font color="blue"><font color="blue">clinical trial</font>s</font>, <font color="blue">regulatory</font> processes,     and sales and <font color="blue">marketing <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">will remain dependent upon</font>     third  party  <font color="blue"><font color="blue">contract research</font> organizations</font> to carry out some of our     clinical and pre-clinical research studies for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As a     result, we have had and will continue to have less control over the conduct     of  the  <font color="blue"><font color="blue">clinical trial</font>s</font>, the timing and <font color="blue">completion</font> of the trials, the     required reporting of <font color="blue">adverse events</font> and the <font color="blue">management</font> of data developed     through the <font color="blue">trial than would</font> be the case if we were <font color="blue">relying entirely upon</font>     our own staff</td>
    </tr>
    <tr>
      <td><font color="blue">Communicating </font><font color="blue">with outside parties</font> can also be <font color="blue">challenging</font>,     <font color="blue">potentially leading</font> to mistakes as well as <font color="blue">difficult</font>ies in <font color="blue">coordinating</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Outside <font color="blue">parties may</font> have staffing <font color="blue">difficult</font>ies, may undergo     changes  in priorities or may become financially distressed, <font color="blue">adversely</font>     <font color="blue">affecting</font> their <font color="blue">willingness</font> or ability to conduct our trials</td>
    </tr>
    <tr>
      <td>We may also     experience <font color="blue">unexpected cost increases</font> that are beyond our control</td>
    </tr>
    <tr>
      <td><font color="blue">Problems     </font>with  the  <font color="blue">timeliness</font>  or  quality  of the work of a <font color="blue">contract research</font>     <font color="blue">organization may lead us</font> to seek to terminate the <font color="blue">relationship</font> and use an     <font color="blue">alternative service provider</font></td>
    </tr>
    <tr>
      <td>However, changing our <font color="blue">service provider may</font> be     costly and may delay our trials, and <font color="blue"><font color="blue">contractual</font> restrictions may</font> make such     a change <font color="blue">difficult</font> or impossible</td>
    </tr>
    <tr>
      <td>Additionally, it may be impossible to find     a <font color="blue">replacement organization</font> that can conduct our trials in an acceptable     manner and at an acceptable cost</td>
    </tr>
    <tr>
      <td>Similarly, we may be unable to <font color="blue">enter into</font> <font color="blue">third party</font> <font color="blue">arrangements</font> for the     marketing and sale of <font color="blue">biopharmaceutical</font>s on acceptable terms</td>
    </tr>
    <tr>
      <td>For certain     products, we may incur substantial expenses to develop our own marketing and     <font color="blue">sales force</font> in order to <font color="blue">commercialize</font> our <font color="blue">biopharmaceutical</font>s and our efforts     may not be successful or the <font color="blue">product may</font> not be approved</td>
    </tr>
    <tr>
      <td>As  a  result we may experience delays in the <font color="blue">commercialization</font> of our     <font color="blue">biopharmaceutical</font>s and we may be unable to compete <font color="blue">effective</font>ly</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">currently lack</font> the resources, <font color="blue">capability</font> and experience <font color="blue">necessary</font>     to  <font color="blue">manufacture</font> <font color="blue">biopharmaceutical</font>s, we <font color="blue">will depend on <font color="blue">third parties</font></font> to     perform  this  function,  which  may  <font color="blue">adversely</font>  affect our ability to     <font color="blue">commercialize</font> any <font color="blue">biopharmaceutical</font>s we may develop</td>
    </tr>
    <tr>
      <td>We do not currently operate <font color="blue">manufacturing facilities</font> for the clinical or     <font color="blue">commercial production</font> of <font color="blue">biopharmaceutical</font>s</td>
    </tr>
    <tr>
      <td>We also lack the resources,     <font color="blue">capability</font> and experience <font color="blue">necessary</font> to <font color="blue">manufacture</font> <font color="blue">biopharmaceutical</font>s</td>
    </tr>
    <tr>
      <td>As a     result, we will depend on <font color="blue">collaborators</font>, partners, licensees and other third     parties to <font color="blue">manufacture</font> clinical and <font color="blue">commercial scale quantities</font> of our     <font color="blue">biopharmaceutical</font> <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">enter into</font> these types of <font color="blue">third party</font>     <font color="blue">arrangements</font>, then we will be <font color="blue">dependent on</font> the efforts of others, which if     not <font color="blue">successful could</font> result in <font color="blue">decreased revenue</font> to us</td>
    </tr>
    <tr>
      <td>To  date  we have identified only a <font color="blue">few facilities</font> that are capable of     producing material for pre-clinical and <font color="blue">clinical studies</font> and we cannot     assure you that they will be able to <font color="blue">supply sufficient <font color="blue">clinical materials</font></font>     during the clinical <font color="blue">development</font> of our <font color="blue">biopharmaceutical</font> <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>is no assurance that <font color="blue">contractors will</font> have the <font color="blue">capacity</font> to <font color="blue">manufacture</font> or     test our <font color="blue">products at</font> the required scale and within the required time frame</td>
    </tr>
    <tr>
      <td>There  is  no  assurance  that the supply of <font color="blue">clinical materials</font> can be     maintained  during  the  clinical <font color="blue">development</font> of our <font color="blue">biopharmaceutical</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We will also be <font color="blue">dependent on</font> contract <font color="blue">manufacture</font>rs to produce     and test any <font color="blue">biopharmaceutical</font>s that are approved for market</td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       Product <font color="blue">liability</font> and other claims <font color="blue"><font color="blue">against us</font> may reduce demand</font> for our     <font color="blue">product candidate</font>s or result in substantial damages</td>
    </tr>
    <tr>
      <td>We face an inherent risk of product <font color="blue">liability</font> exposure related to testing     our <font color="blue">product candidate</font>s in human <font color="blue"><font color="blue">clinical trial</font>s</font> and <font color="blue">will face even greater</font>     risks if we sell our <font color="blue">product candidate</font>s <font color="blue">commercially</font></td>
    </tr>
    <tr>
      <td>An individual may     bring a product <font color="blue">liability</font> claim <font color="blue">against us</font> if one of our <font color="blue">product candidate</font>s     causes, or merely appears to have caused, an injury</td>
    </tr>
    <tr>
      <td>Moreover, in some of     our <font color="blue"><font color="blue">clinical trial</font>s</font>, we test our <font color="blue">product candidate</font>s in <font color="blue">indication</font>s where the     onset  of  certain  symptoms or “attacks” could be fatal</td>
    </tr>
    <tr>
      <td>Although the     protocols for these trials include emergency <font color="blue">treatments</font> in the event a     patient appears to be suffering a potentially fatal incident, patient deaths     <font color="blue">may nonetheless</font> occur</td>
    </tr>
    <tr>
      <td>As a result, we may face <font color="blue">additional</font> <font color="blue">liability</font> if are     found or alleged to be responsible for any such deaths</td>
    </tr>
    <tr>
      <td>These types of product <font color="blue">liability</font> claims may result in:       ·       <font color="blue">decreased demand</font> for our <font color="blue">product candidate</font>s;       ·       injury to our reputation;       ·       withdrawal of <font color="blue">clinical trial</font> volunteers;       ·       related <font color="blue"><font color="blue">litigation</font> costs</font>; and       ·       substantial <font color="blue">monetary awards</font> to plaintiffs</td>
    </tr>
    <tr>
      <td>If  we  fail to establish and maintain strategic license, research and     <font color="blue">collaborative</font>  <font color="blue">relationship</font>s,  or if our <font color="blue">collaborators</font> are not able to     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> <font color="blue">product candidate</font>s, our ability to     <font color="blue">generate revenues could</font> be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Our business strategy includes leveraging some of our <font color="blue">product candidate</font>s, as     well as our <font color="blue">proprietary</font> <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font>, through <font color="blue">collaborations</font> and     licenses that are structured to generate revenues <font color="blue">through license</font> fees,     technical and <font color="blue">clinical milestone payments</font>, and royalties</td>
    </tr>
    <tr>
      <td>For us to continue     to receive any <font color="blue">significant</font> payments from our licenses and <font color="blue">collaborations</font>,     the  relevant <font color="blue">product candidate</font>s must advance through <font color="blue"><font color="blue">clinical trial</font>s</font>,     <font color="blue">establish safety</font> and efficacy, and achieve <font color="blue">regulatory</font> approvals and market     <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>In  general,  however,  under  our  existing  license and     <font color="blue">collaboration <font color="blue"><font color="blue">agreement</font>s</font></font>, our licensees and <font color="blue">collaborators</font>:       ·       are not obligated to develop or market <font color="blue">product candidate</font>s discovered     using our <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font>;       ·       may pursue alternative <font color="blue">technologies</font> or develop <font color="blue">competing products</font>;       ·       control many of the <font color="blue"><font color="blue">decisions</font> <font color="blue">with respect</font></font> to research, clinical     trials and <font color="blue">commercialization</font> of <font color="blue">product candidate</font>s we discover or develop     with them;       ·        may  terminate their <font color="blue">collaborative</font> <font color="blue">arrangements</font> with us under     <font color="blue">specified circumstances</font>, including, for example, a change of control, with     short notice; and       ·       <font color="blue">may disagree with us as</font> to whether a milestone or <font color="blue">royalty payment</font> is     due or as to the amount that is due under the terms of our <font color="blue">collaborative</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will be able to maintain our current licensing     and <font color="blue">collaborative</font> efforts nor can we assure the success of any current or     <font color="blue">future licensing</font> and <font color="blue">collaborative</font> <font color="blue">relationship</font>s</td>
    </tr>
    <tr>
      <td>If any <font color="blue">significant</font> portion     of our licensing and <font color="blue">collaborative</font> efforts fail, our business and financial     condition would be <font color="blue">materially</font> harmed</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       We and our <font color="blue">collaborators</font> may not be able to gain market <font color="blue">acceptance</font> of our     <font color="blue">biopharmaceutical</font>s, which could <font color="blue"><font color="blue">adversely</font> affect</font> our revenues</td>
    </tr>
    <tr>
      <td>We cannot be certain that any of our <font color="blue">biopharmaceutical</font> <font color="blue">candidates</font>, even if     <font color="blue">successfully</font>  approved,  will gain market <font color="blue">acceptance</font> among physicians,     patients, healthcare payors, pharmaceutical <font color="blue">manufacture</font>rs or others</td>
    </tr>
    <tr>
      <td>We may     not achieve market <font color="blue">acceptance</font> even if <font color="blue"><font color="blue">clinical trial</font>s</font> <font color="blue">demonstrate</font> safety and     efficacy of our <font color="blue">biopharmaceutical</font> <font color="blue">candidates</font> and the <font color="blue">necessary</font> <font color="blue">regulatory</font>     and <font color="blue">reimbursement approvals</font> are obtained</td>
    </tr>
    <tr>
      <td>The degree of market <font color="blue">acceptance</font> of     our  <font color="blue">biopharmaceutical</font>  <font color="blue">candidates</font> will depend on a number of factors,     including:       ·       their <font color="blue">clinical efficacy</font> and safety;       ·       their cost-<font color="blue">effective</font>ness;       ·       their potential advantage over alternative treatment methods;       ·       their marketing and <font color="blue">distribution support</font>;       ·       <font color="blue">reimbursement policies</font> of <font color="blue">government</font> and third-party payors; and       ·       <font color="blue">market penetration</font> and <font color="blue">pricing strategies</font> of competing and future     products</td>
    </tr>
    <tr>
      <td>If our products do not achieve <font color="blue">significant</font> market <font color="blue">acceptance</font>, our revenues     could be <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>and <font color="blue">technological</font> change may make our potential products and     <font color="blue">technologies</font> less attractive or obsolete</td>
    </tr>
    <tr>
      <td>We compete in <font color="blue">industries characterized by intense competition</font> and rapid     <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>New <font color="blue">development</font>s occur and are expected to continue to     occur  at  a rapid pace</td>
    </tr>
    <tr>
      <td><font color="blue">Discoveries </font>or commercial <font color="blue">development</font>s by our     <font color="blue"><font color="blue">competitor</font>s</font>  may  render  some or all of our <font color="blue">technologies</font>, products or     potential products obsolete or non-competitive</td>
    </tr>
    <tr>
      <td>Our <font color="blue">principal focus</font> is on the <font color="blue">development</font> of <font color="blue">therapeutic products</font></td>
    </tr>
    <tr>
      <td>We will     conduct  research and <font color="blue">development</font> programs to develop and <font color="blue">test product</font>     <font color="blue">candidates</font> and <font color="blue">demonstrate</font> to appropriate <font color="blue">regulatory</font> agencies that these     products  are  safe  and  <font color="blue">effective</font>  for <font color="blue">therapeutic use</font> in particular     <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Therefore </font>our principal competition going forward, as further     described below, will be companies who either are <font color="blue">already marketing products</font>     in those <font color="blue">indication</font>s or are developing <font color="blue">new products</font> for those <font color="blue">indication</font>s</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have greater financial resources and experience than     we do</td>
    </tr>
    <tr>
      <td>For DX-88 as a treatment for HAE, our principal <font color="blue"><font color="blue">competitor</font>s</font> include ZLB     Behring, Jerini, Pharming Group NV, and Lev Pharmaceuticals</td>
    </tr>
    <tr>
      <td><font color="blue">ZLB Behring     </font><font color="blue">currently markets</font> a plasma-derived C1 <font color="blue">esterase inhibitor</font> that is approved     for the treatment of HAE in several European countries</td>
    </tr>
    <tr>
      <td>ZLB Behring has     initiated a Phase II/III <font color="blue">clinical trial</font> of its plasma-derived C1 esterase     inhibitor in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Jerini has received a <font color="blue">Fast Track </font><font color="blue">designation</font>     from the FDA, as well as orphan drug <font color="blue">designation</font>s from both the <font color="blue"><font color="blue">FDA and EMEA </font>    </font>for its <font color="blue">bradykinin</font> receptor <font color="blue">antagonist</font></td>
    </tr>
    <tr>
      <td>Jerini has initiated <font color="blue">Phase III </font>    <font color="blue"><font color="blue">clinical trial</font>s</font> in both the <font color="blue">United States</font> and Europe</td>
    </tr>
    <tr>
      <td>Pharming has received     orphan drug <font color="blue">designation</font>s from both the <font color="blue">FDA and EMEA </font>for its <font color="blue">recombinant</font> C1     inhibitor and has initiated <font color="blue">Phase III </font><font color="blue"><font color="blue">clinical trial</font>s</font> in both the United     States and Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Lev Pharmaceuticals </font>has received both <font color="blue">Fast Track </font>and     orphan drug <font color="blue">designation</font>s from the FDA for its plasma-derived C1 esterase     inhibitor and has initiated a <font color="blue">Phase III </font><font color="blue">clinical trial</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Other  <font color="blue"><font color="blue">competitor</font>s</font>  include  companies  that  market or are developing     <font color="blue">corticosteroid drugs</font> or other anti-inflammatory compounds</td>
    </tr>
    <tr>
      <td>For  DX-88 as a treatment for <font color="blue">reducing <font color="blue">blood loss</font></font> in CABG surgery, our     principal   <font color="blue">competitor</font>   is   Bayer   AG,   which   currently  markets     Trasylol® (aprotinin) for the reduction of <font color="blue">blood loss</font> in CABG patients</td>
    </tr>
    <tr>
      <td>A       20     ______________________________________________________________________       number  of  other  companies,  including  Novo  Nordisk,  and  Inspire     Pharmaceutical, as well as Vanderbilt University, are developing products     for this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>For   potential   oncology   product  <font color="blue">candidates</font>  coming  out  of  our     <font color="blue">biopharmaceutical</font>  <font color="blue">discovery</font>  and  <font color="blue">development</font> programs, our potential     <font color="blue"><font color="blue">competitor</font>s</font> include <font color="blue">numerous pharmaceutical</font> and bio<font color="blue">technology</font> companies,     most of which have <font color="blue">substantially greater financial resources</font> and experience     than we do</td>
    </tr>
    <tr>
      <td>In addition, most large <font color="blue">pharmaceutical companies seek</font> to develop orally     available small molecule <font color="blue">compounds against</font> many of the targets for which     others and we are seeking to develop antibody, peptide and/or small protein     products</td>
    </tr>
    <tr>
      <td>Our <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font> is one of several <font color="blue">technologies</font> available to     <font color="blue">generate libraries</font> of compounds that can be used to discover and develop new     antibody, peptide and/or small <font color="blue">protein products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">primary competing</font>     <font color="blue">technology</font> platforms that pharmaceutical, diagnostics and bio<font color="blue">technology</font>     <font color="blue">companies use</font> to identify <font color="blue">antibodies</font> that bind to a desired target are     transgenic  mouse <font color="blue">technology</font> and the <font color="blue">humanization</font> of murine <font color="blue">antibodies</font>     <font color="blue"><font color="blue">derived from</font> hybridomas</font></td>
    </tr>
    <tr>
      <td>are leaders in these <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Further, we license our     phage  <font color="blue">display patents</font> and libraries to other parties in the fields of     <font color="blue">therapeutics</font> and <font color="blue">diagnostic product</font>s on a non-exclusive basis</td>
    </tr>
    <tr>
      <td>Our licensees     may  compete  with  us  in the <font color="blue">development</font> of <font color="blue">specific therapeutic</font> and     <font color="blue">diagnostic product</font>s</td>
    </tr>
    <tr>
      <td>In particular, <font color="blue">Cambridge Antibody Technology Group </font>plc     (CAT), Morphosys AG, and BioInvent International AB, all of which have     licenses  to  our  base  <font color="blue">technology</font>,  compete with us, both to develop     <font color="blue">therapeutics</font> and to <font color="blue">offer research services</font> to <font color="blue">larger pharmaceutical</font> and     bio<font color="blue">technology</font>  companies</td>
    </tr>
    <tr>
      <td>Biosite Incorporated, which is also a patent     licensee of ours, has <font color="blue">partnered with</font> Medarex, Inc</td>
    </tr>
    <tr>
      <td>to <font color="blue">combine <font color="blue">phage display</font></font>     <font color="blue">technology</font> with transgenic mouse <font color="blue">technology</font> to create <font color="blue">antibody libraries</font>     <font color="blue">derived from</font> the RNA of immunized mice</td>
    </tr>
    <tr>
      <td>Other companies are attempting to     develop new antibody engineering <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These include CAT, which is     developing ribosomal <font color="blue">display <font color="blue">technology</font></font> and <font color="blue">antibody mimics</font>, Diversa Corp,     which  is developing <font color="blue">combinatorial arrays</font> for large-scale screening of     <font color="blue">antibodies</font>, our <font color="blue">patent licensee</font> Domantis Limited, which makes <font color="blue">single domain</font>     <font color="blue">antibody libraries</font>, and Novagen, Inc, which is developing <font color="blue">cDNA display</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, we may experience <font color="blue">competition from companies</font> that have acquired     or may acquire <font color="blue">technology</font> from universities and other <font color="blue">research institutions</font></td>
    </tr>
    <tr>
      <td>As these companies develop their <font color="blue">technologies</font>, they may develop <font color="blue">proprietary</font>     positions  that  may  prevent us from <font color="blue">successfully</font> <font color="blue">commercializing</font> our     products</td>
    </tr>
    <tr>
      <td>Our success depends <font color="blue">significant</font>ly upon our ability to obtain and maintain     <font color="blue"><font color="blue">intellectual</font> property</font> protection for our products and <font color="blue">technologies</font> and third     parties not obtaining patents that <font color="blue">would prevent us from <font color="blue">commercializing</font></font> any     of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks</font> and <font color="blue">uncertainties</font> related to our <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>For example:       ·       we may be unable to obtain or maintain patent or other <font color="blue">intellectual</font>     <font color="blue">property protection</font> for any products or processes that we may develop;       ·       third <font color="blue">parties may</font> obtain patents covering the <font color="blue">manufacture</font>, use or     sale of these products, which <font color="blue">may prevent us from <font color="blue">commercializing</font></font> any of our     products under <font color="blue">development</font> globally or in <font color="blue">certain regions</font>; or       ·       our patents or any <font color="blue">future patents</font> that we may obtain may not prevent     other  <font color="blue">companies from competing with us by designing</font> their products or     conducting their <font color="blue">activities</font> so as to avoid the coverage of our patents</td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________       Our <font color="blue"><font color="blue">phage display</font> <font color="blue">patent rights</font></font> are central to our non-exclusive patent     <font color="blue">licensing program</font></td>
    </tr>
    <tr>
      <td>As part of that <font color="blue">licensing program</font>, we <font color="blue">generally seek</font> to     negotiate  a  phage  <font color="blue">display license <font color="blue">agreement</font> with parties practicing</font>     <font color="blue">technology</font> covered by our patents</td>
    </tr>
    <tr>
      <td>In countries where we do not have and/or     have not applied for <font color="blue"><font color="blue">phage display</font> <font color="blue">patent rights</font></font>, we will be unable to     <font color="blue">prevent others from <font color="blue">using <font color="blue">phage display</font></font></font> or developing or <font color="blue">selling products</font> or     <font color="blue">technologies</font> derived <font color="blue">using <font color="blue">phage display</font></font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">jurisdictions</font>     where we have <font color="blue"><font color="blue">phage display</font> <font color="blue">patent rights</font></font>, we may be unable to prevent     <font color="blue">others from selling</font> or <font color="blue">importing products</font> or <font color="blue">technologies</font> derived elsewhere     <font color="blue">using <font color="blue">phage display</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to protect and enforce our <font color="blue">phage display</font>     <font color="blue">patent rights</font>, whether by licensing or any <font color="blue">invalidity</font> of our patents or     otherwise, would <font color="blue">negatively</font> affect our research and revenues</td>
    </tr>
    <tr>
      <td>In  all of our <font color="blue">activities</font>, we also rely substantially upon <font color="blue">proprietary</font>     materials, information, <font color="blue">trade secrets</font> and know-how to conduct our research     and  <font color="blue">development</font>  <font color="blue">activities</font>  and to attract and retain <font color="blue">collaborators</font>,     licensees and customers</td>
    </tr>
    <tr>
      <td>Although we take steps to protect our <font color="blue">proprietary</font>     rights and information, including the use of <font color="blue">confidentiality</font> and other     <font color="blue"><font color="blue">agreement</font>s</font>  with our employees and <font color="blue">consultants</font> and in our academic and     commercial <font color="blue">relationship</font>s, these steps may be inadequate, these <font color="blue"><font color="blue">agreement</font>s</font>     may  be  violated,  or there may be <font color="blue">no adequate remedy available</font> for a     violation</td>
    </tr>
    <tr>
      <td>Also, our <font color="blue">trade secrets</font> or similar <font color="blue">technology</font> may otherwise     become  known  to, or be <font color="blue"><font color="blue">independent</font>ly</font> developed or <font color="blue">duplicated by</font>, our     <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Before  we  and  our <font color="blue">collaborators</font> can market some of our processes or     products, we and our <font color="blue">collaborators</font> may need to obtain <font color="blue">licenses from</font> other     parties who have patent or other <font color="blue"><font color="blue">intellectual</font> property</font> rights covering those     processes or products</td>
    </tr>
    <tr>
      <td>Third parties have <font color="blue">patent rights</font> related to phage     display, <font color="blue">particularly</font> in the area of <font color="blue">antibodies</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">gained access</font>     to <font color="blue">key patents</font> in the <font color="blue">antibody area through</font> the <font color="blue">cross licenses with</font> Affimed     Therapeutics AG, Affitech AS, Biosite Incorporated, Genentech, Inc, XOMA     Ireland Limited and Cambridge Antibody Technology Limited, other <font color="blue">third party</font>     patent owners may contend that we need a license or other <font color="blue">rights under</font> their     patents in order for us to <font color="blue">commercialize</font> a process or product</td>
    </tr>
    <tr>
      <td>In addition,     we may choose to license <font color="blue">patent rights</font> from other <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In order     for us to <font color="blue">commercialize</font> a process or product, we may need to license the     <font color="blue">patent rights</font> of other parties</td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font> does not offer us a needed     license or offers us a <font color="blue">license only on</font> terms that are unacceptable, we may     be unable to <font color="blue">commercialize</font> one or more of our products</td>
    </tr>
    <tr>
      <td>If a <font color="blue">third party</font>     does not offer a needed license to our <font color="blue">collaborators</font> and as a result our     <font color="blue">collaborators</font> stop work under their <font color="blue">agreement</font> with us, we might lose future     milestone payments and royalties</td>
    </tr>
    <tr>
      <td>If we decide not to seek a license, or if     licenses are not <font color="blue"><font color="blue">available on</font> <font color="blue">reasonable terms</font></font>, we may become subject to     <font color="blue">infringement</font>  claims or other legal <font color="blue">proceedings</font>, which could result in     substantial <font color="blue">legal expenses</font></td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in these actions, adverse     <font color="blue">decisions</font>  <font color="blue">may prevent us from <font color="blue">commercializing</font></font> the <font color="blue">affected process</font> or     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">seek affirmative rights</font> of license or <font color="blue">ownership under existing patent</font>     rights relating to <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font> of others</td>
    </tr>
    <tr>
      <td>For example, through     our patent <font color="blue">licensing program</font>, we have secured a limited freedom to practice     some of these <font color="blue">patent rights</font> pursuant to our standard license <font color="blue">agreement</font>,     <font color="blue">which contains</font> a <font color="blue">covenant by</font> the licensee that it will not <font color="blue">sue us under</font>     certain of the licensee’s <font color="blue">phage display</font> improvement patents</td>
    </tr>
    <tr>
      <td>We cannot     guarantee, however, that we will be successful in enforcing any <font color="blue"><font color="blue">agreement</font>s</font>     from  our licensees, including <font color="blue"><font color="blue">agreement</font>s</font> not to sue under their phage     <font color="blue">display improvement patents</font>, or in acquiring similar <font color="blue"><font color="blue">agreement</font>s</font> in the     future, or that we will be able to obtain <font color="blue">commercially</font> satisfactory licenses     to the <font color="blue">technology</font> and patents of others</td>
    </tr>
    <tr>
      <td>If we cannot obtain and maintain     these licenses and enforce these <font color="blue"><font color="blue">agreement</font>s</font>, this could have a negative     effect on our business</td>
    </tr>
    <tr>
      <td><font color="blue">Proceedings </font>to obtain, enforce or defend patents and to <font color="blue">defend against</font>     charges  of  <font color="blue">infringement</font> are time consuming and expensive <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>outcomes in these <font color="blue"><font color="blue">proceedings</font> could limit</font> our <font color="blue">patent rights</font> and     our <font color="blue">activities</font>, which could <font color="blue">materially</font> affect our business</td>
    </tr>
    <tr>
      <td>Obtaining, protecting and <font color="blue">defending against patent</font> and <font color="blue">proprietary</font> rights     can be expensive</td>
    </tr>
    <tr>
      <td>For example, if a <font color="blue">competitor</font> files a <font color="blue">patent application</font>     claiming <font color="blue">technology</font> also invented by us, we may have to <font color="blue">participate</font> in an     expensive and time-consuming interference proceeding before the <font color="blue">US Patent     </font>and       22     ______________________________________________________________________       <font color="blue">Trademark Office </font>to address who was first to invent the subject matter of     the claim and whether that subject matter was patentable</td>
    </tr>
    <tr>
      <td>Moreover, an     unfavorable outcome in an <font color="blue">interference proceeding could</font> require us to cease     using  the  <font color="blue">technology</font>  or to attempt to <font color="blue">license rights</font> to it from the     <font color="blue">prevailing party</font></td>
    </tr>
    <tr>
      <td>Our business would be harmed if a prevailing <font color="blue">third party</font>     does not offer us a <font color="blue">license on terms</font> that are acceptable to us</td>
    </tr>
    <tr>
      <td>In <font color="blue">patent offices outside</font> the <font color="blue">United States</font>, we may be forced to respond to     <font color="blue">third party</font> challenges to our patents</td>
    </tr>
    <tr>
      <td>For example, our first <font color="blue">phage display</font>     patent in Europe, European Patent Nodtta 436cmam597, known as the 597 Patent, was     <font color="blue">ultimately revoked</font> in 2002 in <font color="blue">proceedings</font> in the <font color="blue">European Patent Office</font></td>
    </tr>
    <tr>
      <td>We     have two divisional <font color="blue">patent application</font>s of the 597 Patent pending in the     <font color="blue">European Patent Office</font></td>
    </tr>
    <tr>
      <td>We will not be able to prevent other <font color="blue">parties from</font>     using our <font color="blue">phage <font color="blue">display <font color="blue">technology</font></font></font> in Europe if the <font color="blue">European Patent Office</font>     does not grant us another patent</td>
    </tr>
    <tr>
      <td>We cannot be assured that we <font color="blue">will prevail</font>     in the <font color="blue">prosecution</font> of either of these <font color="blue">patent application</font>s</td>
    </tr>
    <tr>
      <td>The  issues  relating  to  the  validity,  <font color="blue">enforceability</font> and possible     <font color="blue">infringement</font> of our <font color="blue">patents present complex</font> factual and <font color="blue">legal issues</font> that we     <font color="blue">periodically reevaluate</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">gained access</font>     to <font color="blue">key patents</font> in the <font color="blue">antibody area through</font> our cross-licensing <font color="blue">agreement</font>     with Affimed, Affitech, Biosite, Genentech, XOMA and CAT, other <font color="blue">third party</font>     patent owners may contend that we need a license or other <font color="blue">rights under</font> their     patents in order for us to <font color="blue">commercialize</font> a process or product</td>
    </tr>
    <tr>
      <td>In addition,     we may choose to license <font color="blue">patent rights</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>While we believe     that we will be able to obtain any needed licenses, we <font color="blue">cannot assure</font> that     these licenses, or licenses to other <font color="blue">patent rights</font> that we identify as     <font color="blue">necessary</font> in the future, will be <font color="blue"><font color="blue">available on</font> <font color="blue">reasonable terms</font></font>, if at all</td>
    </tr>
    <tr>
      <td>If we decide not to seek a license, or if licenses are not <font color="blue">available on</font>     <font color="blue">reasonable terms</font>, we may become subject to <font color="blue">infringement</font> claims or other     legal <font color="blue">proceedings</font>, which could result in substantial <font color="blue">legal expenses</font></td>
    </tr>
    <tr>
      <td>have sued us     in a variety of patent <font color="blue">infringement</font> actions since 1999, all of which have     been  dismissed  and  no  appeals  are <font color="blue">pending at</font> this time</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">unsuccessful</font>  in  these actions, adverse <font color="blue">decisions</font> may prevent us from     <font color="blue">commercializing</font> the <font color="blue">affected process</font> or products</td>
    </tr>
    <tr>
      <td>Moreover, if we are unable     to maintain the <font color="blue">covenants with</font> regard to <font color="blue">phage display</font> improvements that we     obtain from our <font color="blue">licensees through</font> our patent <font color="blue">licensing program</font> and the     licenses that we have obtained to <font color="blue">third party</font> <font color="blue"><font color="blue">phage display</font> <font color="blue">patent rights</font></font> it     could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We incurred substantial costs as a result of the <font color="blue">Pieczenik </font><font color="blue">litigation</font> and we     would  expect  to incur substantial costs in <font color="blue">connection with</font> any other     <font color="blue">litigation</font> or <font color="blue">patent proceeding</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">management</font>’s efforts would     be diverted, regardless of the results of the <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>An unfavorable     result could subject us to <font color="blue">significant</font> liabilities to <font color="blue">third parties</font>, require     us to <font color="blue">cease manufacturing</font> or selling the <font color="blue">affected products</font> or using the     <font color="blue">affected process</font>es, require us to license the <font color="blue">disputed rights from third</font>     parties or result in awards of substantial damages <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Our business     will be harmed if we cannot obtain a license, can obtain a <font color="blue">license only on</font>     terms we consider to be unacceptable or if we are unable to redesign our     products or processes to avoid <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>In all of our <font color="blue">activities</font>, we substantially rely on <font color="blue">proprietary</font> materials and     information, <font color="blue">trade secrets</font> and know-how to <font color="blue">conduct research</font> and <font color="blue">development</font>     <font color="blue">activities</font> and to attract and retain <font color="blue">collaborative</font> partners, licensees and     customers</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  take  steps  to  protect these materials and     information, including the use of <font color="blue">confidentiality</font> and other <font color="blue"><font color="blue">agreement</font>s</font> with     our employees and <font color="blue">consultants</font> in <font color="blue">both academic</font> and commercial <font color="blue">relationship</font>s,     we  cannot  assure  you  that these steps will be adequate, that these     <font color="blue"><font color="blue">agreement</font>s</font> will not be violated, or that <font color="blue">there will</font> be an available or     <font color="blue">sufficient remedy</font> for any <font color="blue">such violation</font>, or that <font color="blue">others will</font> not also     develop similar <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       Our revenues and operating results have fluctuated <font color="blue">significant</font>ly in the     past, and we expect this to continue in the future</td>
    </tr>
    <tr>
      <td>Our  revenues and operating results have fluctuated <font color="blue">significant</font>ly on a     quarter to <font color="blue">quarter basis</font></td>
    </tr>
    <tr>
      <td>We expect these <font color="blue">fluctuations</font> to continue in the     future</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in revenues and operating results will depend on:       ·       the timing of our increased research and <font color="blue">development</font> expenses;       ·       the <font color="blue">establishment</font> of new <font color="blue">collaborative</font> and licensing <font color="blue">arrangements</font>;       ·       the timing and results of <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·       the <font color="blue">development</font> and marketing programs of current and prospective     <font color="blue">collaborators</font>; and       ·       the <font color="blue">completion</font> of certain <font color="blue">milestones</font></td>
    </tr>
    <tr>
      <td>If the revenues we receive are less than the revenues we expect for a given     fiscal period, then we may be unable to reduce our <font color="blue">expenses quickly enough</font>     to  compensate for the shortfall</td>
    </tr>
    <tr>
      <td>Our revenues in any period are not a     <font color="blue">reliable indicator</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">fluctuating</font>     revenues  and  operating  results may fail to meet the <font color="blue">expectations</font> of     <font color="blue">securities analysts</font> or investors</td>
    </tr>
    <tr>
      <td>Our failure to meet these <font color="blue">expectations</font> may     cause the price of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>If we lose or are unable to hire and retain <font color="blue">qualified personnel</font>, then we may     not be able to develop our products or processes</td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent on</font> qualified scientific and <font color="blue">management</font> personnel,     and  we <font color="blue">face intense competition from</font> other companies and research and     <font color="blue">academic institutions</font> for <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>If we lose an executive     officer,  a manager of one of our principal business units or research     programs, or a <font color="blue">significant</font> number of any of our staff or are unable to hire     and  retain  qualified  personnel,  then  our  ability  to develop and     <font color="blue">commercialize</font> our products and <font color="blue">processes may</font> be delayed or prevented</td>
    </tr>
    <tr>
      <td>We use and <font color="blue">generate <font color="blue">hazardous</font> materials</font> in our business, and any claims     relating to the improper handling, storage, release or disposal of these     <font color="blue">materials could</font> be time-consuming and expensive</td>
    </tr>
    <tr>
      <td>Our <font color="blue">phage display</font> research and <font color="blue">development</font> involves the <font color="blue">controlled storage</font>,     use  and disposal of <font color="blue">chemicals</font> and solvents, as well as biological and     <font color="blue">radioactive materials</font></td>
    </tr>
    <tr>
      <td>We are subject to foreign, federal, state and local     laws and <font color="blue"><font color="blue">regulations</font> governing</font> the use, <font color="blue">manufacture</font> and storage and the     handling and disposal of materials and <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td>Although we believe     that our <font color="blue">safety procedures</font> for handling and disposing of these <font color="blue">hazardous</font>     <font color="blue">materials comply with</font> the <font color="blue">standards prescribed by laws</font> and <font color="blue">regulations</font>, we     cannot  <font color="blue">completely</font>  eliminate the risk of <font color="blue">contamination</font> or <font color="blue">injury from</font>     <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>If an <font color="blue">accident</font> occurs, an injured party could seek to     hold us liable for any damages that result and any <font color="blue">liability</font> could exceed     the limits or <font color="blue">fall outside</font> the coverage of our insurance</td>
    </tr>
    <tr>
      <td>We may incur     <font color="blue">significant</font> costs to <font color="blue">comply with current</font> or <font color="blue">future environmental laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We may have <font color="blue">significant</font> product <font color="blue">liability</font> exposure</td>
    </tr>
    <tr>
      <td>We  <font color="blue">face exposure</font> to product <font color="blue">liability</font> and other claims if products or     processes are alleged to have caused harm</td>
    </tr>
    <tr>
      <td>These risks are inherent in the     testing, manufacturing and marketing of human <font color="blue">therapeutic products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>   we  currently  maintain  product  <font color="blue">liability</font> insurance, we may not have     sufficient insurance coverage, and we may not be able to obtain sufficient     <font color="blue">coverage at</font> a <font color="blue">reasonable cost</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to obtain product <font color="blue">liability</font>     <font color="blue">insurance at</font> an acceptable cost or to <font color="blue">otherwise protect against potential</font>     product <font color="blue">liability</font> claims <font color="blue">could prevent</font> or inhibit the <font color="blue">commercialization</font> of     any products that we or our <font color="blue">collaborators</font> develop</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       If we are sued for any injury caused by our products or processes, then our     <font color="blue">liability</font> could exceed our product <font color="blue">liability</font> insurance coverage and our     <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td>Our business is subject to risks associated with international <font color="blue">operations</font>     and <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>We  receive  product  <font color="blue">development</font>  and <font color="blue">license fees from international</font>     <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, we <font color="blue">earned revenue</font> of     approximately dlra8dtta9 million from non-US based companies</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">international product</font>     <font color="blue">development</font> and <font color="blue">license fees will continue</font> to account for a <font color="blue">significant</font>     percentage of our revenues for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, we have     direct  <font color="blue">investment</font>s in <font color="blue">subsidiaries located</font> in the <font color="blue">European Union</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">operations</font>  could be limited or disrupted, and the value of our direct     <font color="blue">investment</font>s may be diminished, by any of the following:       ·       <font color="blue">fluctuations</font> in <font color="blue">currency <font color="blue">exchange rate</font>s</font>;       ·       the imposition of <font color="blue">government</font>al controls;       ·       less favorable <font color="blue"><font color="blue">intellectual</font> property</font> or other <font color="blue">applicable laws</font>;       ·       the <font color="blue">inability</font> to obtain any <font color="blue">necessary</font> foreign <font color="blue">regulatory</font> approvals     of products in a <font color="blue">timely manner</font>;       ·       import and <font color="blue">export license requirements</font>;       ·       <font color="blue">political instability</font>;       ·       terrorist <font color="blue">activities</font>; and       ·       <font color="blue">difficult</font>ies in staffing and managing international <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We recognize <font color="blue"><font color="blue">foreign currency</font> gains</font> or     losses arising from our <font color="blue">operations</font> in the period in which we incur those     gains or losses</td>
    </tr>
    <tr>
      <td>As a result, currency <font color="blue">fluctuations</font> among the US dollar     and the currencies in which we do business have caused <font color="blue">foreign currency</font>     <font color="blue">transaction</font>  gains and losses in the past and <font color="blue">will likely</font> do so in the     future</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">variability</font> of <font color="blue">currency exposures</font> and the potential     <font color="blue">volatility</font> of <font color="blue">currency <font color="blue">exchange rate</font>s</font>, we may suffer <font color="blue">significant</font> foreign     currency <font color="blue">transaction</font> losses in the future due to the effect of <font color="blue">exchange rate</font>     <font color="blue">fluctuations</font> on our future operating results</td>
    </tr>
    <tr>
      <td>If we fail to maintain an <font color="blue">effective</font> system of <font color="blue">internal controls</font> in the     future, we may not be able to <font color="blue">accurately</font> report our financial results or     <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td>The Sarbanes-Oxley Act of 2002 requires that we report annually on the     <font color="blue">effective</font>ness of our <font color="blue">internal controls</font> over financial reporting</td>
    </tr>
    <tr>
      <td>Among other     things, we must perform systems and processes <font color="blue">evaluation</font> and testing</td>
    </tr>
    <tr>
      <td>We     <font color="blue">must also conduct</font> an <font color="blue">assessment</font> of our <font color="blue">internal controls</font> to allow <font color="blue">management</font>     to report on, and our <font color="blue"><font color="blue">independent</font> registered public accounting firm</font> to     attest to, our <font color="blue">assessment</font> of our <font color="blue">internal controls</font> over financial reporting,     as required by Section 404 of the Sarbanes-Oxley Act</td>
    </tr>
    <tr>
      <td>In the future, our     continued  <font color="blue">assessment</font>, or the subsequent <font color="blue">assessment</font> by our <font color="blue">independent</font>     registered public accounting firm, may reveal <font color="blue">significant</font> <font color="blue">deficiencies</font> or     material <font color="blue">weaknesses</font> in our <font color="blue">internal controls</font>, which may need to be disclosed     in future Annual Reports on Form 10-K <font color="blue">Disclosures </font>of this type could cause     investors to lose confidence in our financial reporting and may <font color="blue">negatively</font>     affect the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">effective</font> <font color="blue">internal controls</font>     are <font color="blue">necessary</font> to produce <font color="blue">reliable financial</font> reports and to <font color="blue">prevent fraud</font></td>
    </tr>
    <tr>
      <td>If     we have <font color="blue">deficiencies</font> in our <font color="blue">internal controls</font> over financial reporting, it     may <font color="blue">negatively</font> impact our business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       <font color="blue">Compliance </font>with changing regulation of <font color="blue">corporate governance</font> and public     <font color="blue">disclosure may</font> result in <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td>Keeping abreast of, and in <font color="blue">compliance with</font>, changing laws, <font color="blue">regulations</font>, and     standards relating to <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>, including     the Sarbanes-Oxley Act of 2002, new SEC <font color="blue">regulations</font>, and <font color="blue"><font color="blue">NASDAQ Stock Market </font>    </font>rules,  have  required an <font color="blue">increased amount</font> of <font color="blue">management</font> attention and     <font color="blue">external resources</font></td>
    </tr>
    <tr>
      <td>We intend to invest all reasonably <font color="blue">necessary</font> resources     to  comply  with  evolving  <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>     standards,  and  this  <font color="blue">investment</font>  may result in <font color="blue">increased general</font> and     <font color="blue">administrative expenses</font> and a diversion of <font color="blue">management</font> time and attention     from revenue-generating <font color="blue">activities</font> to compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We may not succeed in acquiring <font color="blue">technology</font> and <font color="blue">integrating complementary</font>     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We may acquire <font color="blue">additional</font> <font color="blue">technology</font> and complementary <font color="blue">businesses</font> in the     future</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>involve many risks, any one of which could <font color="blue">materially</font>     harm our business, including:       ·       the diversion of <font color="blue">management</font>’s attention from core business concerns;       ·        the  failure  to exploit <font color="blue">effective</font>ly acquired <font color="blue">technologies</font> or     integrate <font color="blue">successfully</font> the acquired <font color="blue">businesses</font>;       ·       the loss of <font color="blue">key employees from either</font> our current business or any     acquired <font color="blue">businesses</font>; and       ·       the <font color="blue">assumption</font> of <font color="blue">significant</font> liabilities of acquired <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We may be unable to make any <font color="blue">future <font color="blue">acquisition</font>s</font> in an <font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">ownership represented by</font> the shares of our <font color="blue">common stock</font> held     by you will be diluted if we <font color="blue">issue equity securities</font> in <font color="blue">connection with</font> any     <font color="blue">acquisition</font></td>
    </tr>
    <tr>
      <td>If  we  make  any  <font color="blue">significant</font>  <font color="blue">acquisition</font>s  using cash     <font color="blue">consideration</font>,  we may be required to use a substantial portion of our     <font color="blue">available cash</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">issue debt securities</font> to finance <font color="blue">acquisition</font>s, then     the <font color="blue">debt holders would</font> have <font color="blue">rights senior</font> to the holders of shares of our     <font color="blue">common stock</font> to make claims on our assets and the terms of any <font color="blue">debt could</font>     restrict our <font color="blue">operations</font>, including our ability to <font color="blue">pay dividends on</font> our     shares  of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisition </font><font color="blue">financing may</font> not be <font color="blue">available on</font>     acceptable terms, or at all</td>
    </tr>
    <tr>
      <td>In addition, we may be required to amortize     <font color="blue">significant</font>  amounts  of  intangible  assets in <font color="blue">connection with</font> future     <font color="blue">acquisition</font>s</td>
    </tr>
    <tr>
      <td>We  <font color="blue">might also</font> have to recognize <font color="blue">significant</font> amounts of     goodwill that will have to be <font color="blue">tested periodically</font> for <font color="blue">impairment</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">amounts could</font> be <font color="blue">significant</font>, which could harm our operating results</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> may continue to have a <font color="blue">volatile public trading price</font> and     <font color="blue">low trading volume</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>Since our     <font color="blue">initial public offering</font> in August 2000 through <font color="blue">February </font>22, 2006, the price     of our <font color="blue">common stock</font> on the <font color="blue">NASDAQ Stock Market </font>has ranged between dlra54dtta12 and     dlra1dtta05</td>
    </tr>
    <tr>
      <td>The market has experienced <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font>     for  many  reasons,  some  of  which may be unrelated to our operating     performance</td>
    </tr>
    <tr>
      <td>Many <font color="blue">factors may</font> have a negative effect on the <font color="blue">market price</font> of our common     stock, including:       ·       public announcements by us, our <font color="blue"><font color="blue">competitor</font>s</font> or others;       ·       <font color="blue">development</font>s concerning <font color="blue">proprietary</font> rights, including patents and     <font color="blue">litigation</font> matters;       ·       publicity regarding actual or potential results <font color="blue">with respect</font> to     products or compounds we or our <font color="blue">collaborators</font> are developing;       ·       <font color="blue">regulatory</font> <font color="blue">development</font>s in both the <font color="blue">United States</font> and abroad;       ·       public concern about the safety or efficacy of new <font color="blue">technologies</font>;       26     ______________________________________________________________________       ·       general market <font color="blue">conditions</font> and comments by <font color="blue">securities analysts</font>; and       ·       quarterly <font color="blue">fluctuations</font> in our revenues and financial results</td>
    </tr>
    <tr>
      <td>Anti-takeover provisions in our <font color="blue">governing documents</font> and under <font color="blue">Delaware </font>law     and  our  <font color="blue">shareholder</font>  rights  plan may make an <font color="blue">acquisition</font> of us more     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>We  are  <font color="blue">incorporated</font> in Delaware</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">various legal</font> and     <font color="blue">contractual</font>  provisions  that  may make a change in control of us more     <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the <font color="blue">flexibility</font> to adopt <font color="blue">additional</font>     anti-takeover measures</td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter authorizes</font> our board of <font color="blue">directors</font> to issue up to 1cmam000cmam000     shares of <font color="blue">preferred stock</font> and to determine the terms of those shares of     stock  without any <font color="blue">further action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If the board of     <font color="blue">directors</font> exercises this power to issue <font color="blue">preferred stock</font>, it could be more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding voting</font>     stock</td>
    </tr>
    <tr>
      <td>Our <font color="blue">charter also provides staggered terms</font> for the members of our     board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>This may prevent <font color="blue">stockholders</font> from replacing the entire     board in a <font color="blue">single proxy contest</font>, making it more <font color="blue">difficult</font> for a <font color="blue">third party</font>     to acquire control of us without the consent of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">equity incentive</font> plans <font color="blue">generally permit</font> our board of <font color="blue">directors</font> to provide     for <font color="blue">acceleration</font> of vesting of <font color="blue">options granted under</font> these plans in the     event of certain <font color="blue">transaction</font>s that result in a change of control</td>
    </tr>
    <tr>
      <td>If our     board of <font color="blue">directors</font> used its authority to <font color="blue">accelerate vesting</font> of options, then     this <font color="blue">action could</font> make an <font color="blue">acquisition</font> more costly, and it <font color="blue">could prevent</font> an     <font color="blue">acquisition</font> from going forward</td>
    </tr>
    <tr>
      <td>Our <font color="blue">shareholder</font> rights plan could result in     the <font color="blue">significant</font> dilution of the <font color="blue">proportionate ownership</font> of any person that     engages in an <font color="blue">unsolicited attempt</font> to take over our company and, <font color="blue">accordingly</font>,     <font color="blue">could discourage potential acquirers</font></td>
    </tr>
    <tr>
      <td>Section 203 of the <font color="blue">Delaware </font>General Corporation Law prohibits a <font color="blue">corporation</font>     from engaging in a business <font color="blue">combination with</font> any holder of 15prca or more of     its  <font color="blue">capital stock until</font> the holder has held the stock for <font color="blue">three years</font>     unless, among other <font color="blue">possibilities</font>, the board of <font color="blue">directors</font> approves the     <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> could use this provision to prevent     changes in <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The provisions described above, as well as other provisions in our charter     and bylaws and under the <font color="blue">Delaware </font>General Corporation Law, may make it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire our company, even if the <font color="blue">acquisition</font>     attempt was at a <font color="blue">premium over</font> the <font color="blue">market value</font> of our <font color="blue">common stock</font> at that     time</td>
    </tr>
  </tbody>
</table>